Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.36 |
| ▸ | CDK9 | P50750 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6769157 | 0.91 | TSHR (0.38) | TSHRNPY5RPPARDMAPTCCNT1 | |
| SCHEMBL8482697 | 0.87 | TSHR (0.47) | TSHRNPY5RNPSR1KCNH2 | |
| SCHEMBL3375825 | 0.86 | TSHR (0.50) | TSHRNPY5RPPARDMAPTCCNT1 | |
| SCHEMBL6999357 | 0.85 | MEN1 (0.41) | NPY5R | |
| SCHEMBL6770911 | 0.83 | PPARD (0.42) | TSHRPPARDNPSR1HDAC1KCNH2 | |
| SCHEMBL6769527 | 0.82 | CYP3A4 (0.42) | — | |
| SCHEMBL6898444 | 0.81 | PPARD (0.42) | TSHRPPARDNPSR1 | |
| SCHEMBL9205796 | 0.81 | — | — | |
| SCHEMBL7001953 | 0.81 | LPAR3 (0.41) | — | |
| SCHEMBL16062693 | 0.80 | POLB (0.46) | TSHRNPY5RPPARDMAPTCCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117136076-A | MCL-1 inhibitor antibody drug conjugates and methods of use | 诺华股份有限公司 | 2023-11-28 | — | — | CN | disclosed |
| US-6720344-B2 | BINDING TO NUCLEAR RECEPTOR PROTEINS; STIMULATING BMP-2 PROMOTER ACTIVITY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2004-04-13 | — | — | US | disclosed |
| EP-1023044-B1 | APATITE-COATED SOLID COMPOSITION | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-02-04 | — | — | EP | disclosed |
| US-20030185878-A1 | Process for producing phospholipid-containing drug | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| US-20030119791-A1 | Methods and compositions for stimulating osteoblast proliferation or treating malignant cell proliferation and methods for selecting osteoblast proliferation stimulants | KERWIN SEAN M (US) | 2003-06-26 | — | — | US | disclosed |
| EP-1069126-B1 | TRIAZOLOPURINE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE DERIVATIVES, ADENOSINE A3 RECEPTOR COMPATIBILIZING AGENT, AND ASTHMATIC REMEDY | OTSUKA PHARMA CO LTD (JP) | 2003-05-28 | — | — | EP | disclosed |
| EP-1293197-A1 | PROCESS FOR PRODUCING PHOSPHOLIPID-CONTAINING DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-03-19 | — | — | EP | disclosed |
| EP-0949927-B1 | PHARMACEUTICAL COMPOSITION CONTAINING OSTEOGENESIS-PROMOTING SUBSTANCE AND A POLYETHYLENE GLYCOL | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-10-16 | — | — | EP | disclosed |
| CN-1090621-C | Process for preparing quinazolin-4-one derivatives | OTSUKA PHARMA CO LTD (JP) | 2002-09-11 | — | — | CN | disclosed |
| EP-1208850-A1 | PASTES WITH THE SUSTAINED RELEASE OF OSTEOGENESIS PROMOTER | Takeda Chemical Industries, Ltd. (JP) | 2002-05-29 | — | — | EP | disclosed |
| WO-1996039134-A1 | OSTEOGENETIC PROMOTING PHARMACEUTICAL COMPOSITION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-12-12 | — | — | WO | disclosed |
| CN-1131948-A | Pyrazolo [1, 5-a ] pyrimidine derivatives | OTSUKA PHARMA CO LTD (JP) | 1996-09-25 | — | — | CN | disclosed |
| EP-0714898-A1 | PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1996-06-05 | — | — | EP | disclosed |
| EP-0550493-B1 | ANTHELMINTIC AND ANTICOCCIDAL 3-CARBAMOYL-4-HYDROXYCOUMARINS, METHOD OF USE AND COMPOSITIONS | UPJOHN CO (US) | 1995-08-09 | — | — | EP | disclosed |
| EP-0376197-B1 | Sulfur-containing heterocyclic compounds | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1994-10-12 | — | — | EP | disclosed |
| US-5158943-A | Osteoporosis | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-10-27 | — | — | US | disclosed |
| EP-0460488-A1 | Sulfur-containing heterocyclic compounds | Takeda Chemical Industries, Ltd. (JP) | 1991-12-11 | — | — | EP | disclosed |
| US-5071841-A | For prevention of bone reabsorption | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-12-10 | — | — | US | disclosed |
| EP-0376197-A1 | Sulfur-containing heterocyclic compounds | Takeda Chemical Industries, Ltd. (JP) | 1990-07-04 | — | — | EP | disclosed |
| EP-0154190-A1 | Pyridones | MERCK PATENT GmbH (DE) | 1985-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030185878-A1 | Process for producing phospholipid-containing drug | PHOSPHO1, PLTP, PTDSS2 | TSHR 3530/4885NPY5R 3772/4885PPARD 658/4885 |
| US-20030119791-A1 | Methods and compositions for stimulating osteoblast proliferation or treating malignant cell proliferation and methods for selecting osteoblast proliferation stimulants | MKI67, HGF, AREG | TSHR 343/4885NPY5R 572/4885PPARD 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.